https://www.selleckchem.com/pr....oducts/disodium-phos
Abnormal maternal serum biomarkers (AMS, identified through the aneuploidy screening programme, are frequent incidental findings in pregnancy. They are associated with fetal growth restriction (FGR), but previous studies have not examined whether this association is with early-onset ( 34 weeks) FGR; as a result there is no consensus on management. The aims of this study were to determine the prevalence and phenotype of FGR in women with AMSB and test the predictive value of placental sonographic screening to predict early-o
Curtir
Comentario
Compartilhar
